NASDAQ$ABUS
Arbutus Biopharma Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter 2024 financial results and provided a corporate update.
Arbutus Biopharma reported a net loss of $17.9 million for the first quarter of 2024, with total revenue of $1.5 million. The company's cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2024, expected to fund operations through the second quarter of 2026.
- Continued progress in advancing pipeline of HBV assets, including imdusiran and AB-101.
- Initiated third Phase 2a trial combining imdusiran with an immune modulator.
- Preliminary data from the single-dose portion of the AB-101-001 clinical trial showed that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects.
- Expected cash runway extended through the second quarter of 2026.
Headline financials
Revenue & EPS history
Arbutus · Revenue · Quarterly
$1.53M
Revenue by segment
Arbutus · $689K total across 1 segment · Q2 2020
- Non-cash Royalty Revenue$689K—100.0%
Forward guidance
Arbutus anticipates its cash reserves will be sufficient to fund operations through the second quarter of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.3%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-0.4%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+22.2%
Q1 2020
Best reaction
-18.6%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -3.2% | — | |
| Q4 2025 | +4.2% | +1.2% | +4.5% | |
| Q3 2025 | -5.8% | -8.1% | -2.7% | |
| Q1 2025 | -0.9% | -1.9% | +10.7% | |
| Q4 2024 | -2.4% | +3.9% | -1.8% | |
| Q3 2024 | -5.8% | -5.8% | -7.1% | |
| Q2 2024 | -0.8% | -4.0% | +2.7% | |
| Q1 2024 | +0.7% | +5.6% | +24.9% | |
| Q4 2023 | -3.1% | -7.3% | -10.4% | |
| Q3 2023 | -0.5% | -5.9% | +10.6% | |
| Q2 2023 | +2.9% | -2.4% | -1.4% | |
| Q1 2023 | +3.6% | +4.0% | +2.8% | |
| Q4 2022 | +1.8% | +4.3% | +7.8% | |
| Q3 2022 | +0.8% | +7.3% | +6.1% | |
| Q2 2022 | +2.8% | +0.0% | -10.2% | |
| Q1 2022 | +1.6% | -20.5% | +8.4% | |
| Q4 2021 | -9.1% | -6.8% | -0.3% | |
| Q3 2021 | -9.6% | -9.1% | +7.8% | |
| Q2 2021 | +9.1% | +13.8% | +23.6% | |
| Q1 2021 | -15.9% | -20.4% | -11.7% | |
| Q4 2020 | -9.3% | -1.1% | -5.8% | |
| Q3 2020 | -8.8% | +5.9% | +31.0% | |
| Q2 2020 | -16.2% | -18.5% | -44.2% | |
| Q1 2020 | +22.2% | +55.6% | +37.0% | |
| Q4 2019 | -2.0% | -8.3% | -70.0% | |
| Q3 2019 | -4.0% | -3.4% | +53.7% | |
| Q2 2019 | +1.2% | +1.2% | -11.0% | |
| Q1 2019 | -5.4% | -10.0% | -36.4% | |
| Q4 2018 | -8.0% | +2.7% | +9.5% | |
| Q3 2018 | +13.7% | -6.7% | -7.4% | |
| Q2 2018 | -18.6% | -19.4% | -23.2% | |
| Q1 2018 | +3.5% | +8.8% | +7.0% | |
| Q4 2017 | -12.5% | -17.5% | -13.3% | |
| Q3 2017 | +20.4% | +4.6% | +2.8% | |
| Q2 2017 | -4.2% | +1.4% | +15.3% | |
| Q1 2017 | -2.4% | -0.9% | +2.1% | |
| Q4 2016 | -6.0% | -4.5% | +0.0% | |
| Q3 2016 | -3.3% | -4.9% | -12.1% | |
| Q2 2016 | -8.6% | -13.6% | -14.5% | |
| Q1 2016 | -3.8% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -2.3% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -5.1% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2013 | -3.1% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +0.6% | — | — | |
| Q2 2012 | -0.3% | — | — | |
| Q1 2012 | -5.1% | — | — | |
| Q4 2011 | +2.9% | — | — | |
| Q4 2010 | +2.9% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | -4.1% | — | — | |
| Q3 2010 | +0.8% | — | — | |
| Q2 2010 | -0.8% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro